Good Pharmacovigilance Practice

The role of Good Pharmacovigilance Practice and Pharmacoepidemiology in Risk Management is mainly to increase the probability of beneficial effects of a drug in a population than the probability of adverse effects and to maintain the Good Reporting Practices by avoiding the major problems in risk management. Also it is important to concentrate on Signal investigation by gathering the information on new or unknown drug effects that is potentially caused by a medicine and that finally should lead to ensuring safety. The pharmacovigilance and clinical trials services providing companies should have the Pharmacovigilance certification.

Market Analysis: The global Pharmacovigilance Market is expected to reach USD 10.27 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness growth at 13.1% CAGR owing to Increasing incidence of ADR is key driver for the growth of pharmacovigilance market. As of 2015, the U.S. FDA received approximately 253,017 serious adverse events and 44,693 deaths associated with adverse drug reactions (ADRs). This shows the potential demand for implementing safety and pharmacovigilance services over the forecast period

Related industrys: TCSNovartisParaxelQuintilesCognizantJubilantBiosysAPCERSun PharmaLambdaINC Research, AlembicSunPharma

Societies and Associations

International Society of PharmacovigilanceClinical Research SocietyJapan CRO AssociationAssociation of Clinical Research ProfessionalsAmerican Association of Pharmaceutical ScientistsPan-Asian Clinical Research AssociationThe Society of Clinical Research Associates,

 

  • Role of pharmacovigilance and pharmacoepidemiology in risk management
  • Good reporting practices
  • Interpreting safety signals
  • Randomized clinical trials
  • Ethical and social aspects of drug use

Related Conference of Good Pharmacovigilance Practice

Good Pharmacovigilance Practice Conference Speakers